X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oxaliplatin (4359) 4359
humans (3862) 3862
oncology (3171) 3171
index medicus (2907) 2907
male (2827) 2827
female (2738) 2738
chemotherapy (2575) 2575
middle aged (2504) 2504
aged (2412) 2412
antineoplastic combined chemotherapy protocols - therapeutic use (2165) 2165
organoplatinum compounds - administration & dosage (1979) 1979
adult (1950) 1950
cancer (1813) 1813
colorectal cancer (1698) 1698
fluorouracil - administration & dosage (1615) 1615
fluorouracil (1592) 1592
colorectal neoplasms - drug therapy (1555) 1555
treatment outcome (1409) 1409
leucovorin (1266) 1266
antineoplastic combined chemotherapy protocols - adverse effects (1186) 1186
colorectal neoplasms - pathology (1156) 1156
irinotecan (1054) 1054
leucovorin - administration & dosage (968) 968
antineoplastic combined chemotherapy protocols - administration & dosage (924) 924
capecitabine (900) 900
5-fluorouracil (861) 861
metastasis (844) 844
deoxycytidine - analogs & derivatives (843) 843
aged, 80 and over (840) 840
disease-free survival (811) 811
organoplatinum compounds - adverse effects (808) 808
pharmacology & pharmacy (801) 801
camptothecin - analogs & derivatives (784) 784
1st-line treatment (783) 783
care and treatment (773) 773
bevacizumab (771) 771
deoxycytidine - administration & dosage (721) 721
cisplatin (712) 712
camptothecin - administration & dosage (680) 680
survival (680) 680
trial (677) 677
therapy (660) 660
neoplasm staging (642) 642
surgery (619) 619
research (612) 612
antineoplastic agents - administration & dosage (611) 611
medicine & public health (603) 603
retrospective studies (581) 581
fluorouracil - adverse effects (565) 565
combination (556) 556
drug administration schedule (553) 553
adenocarcinoma - drug therapy (544) 544
survival rate (544) 544
neoplasm metastasis (533) 533
liver neoplasms - secondary (518) 518
prognosis (513) 513
fluorouracil - analogs & derivatives (509) 509
animals (508) 508
antineoplastic agents (492) 492
carcinoma (472) 472
cetuximab (469) 469
drug therapy (468) 468
liver neoplasms - drug therapy (462) 462
antimitotic agents (454) 454
organoplatinum compounds - therapeutic use (452) 452
analysis (451) 451
cancer therapies (446) 446
clinical trials (433) 433
antineoplastic agents - adverse effects (430) 430
gemcitabine (420) 420
survival analysis (419) 419
antineoplastic agents - therapeutic use (417) 417
colorectal-cancer (405) 405
patients (401) 401
colorectal neoplasms - mortality (400) 400
metastatic colorectal-cancer (400) 400
fluorouracil - therapeutic use (397) 397
phase-ii (373) 373
chemotherapy, adjuvant (368) 368
tumors (365) 365
hematology, oncology and palliative medicine (361) 361
cancer research (357) 357
health aspects (357) 357
folinic acid (351) 351
leucovorin - adverse effects (336) 336
follow-up studies (335) 335
kaplan-meier estimate (327) 327
dose-response relationship, drug (326) 326
toxicity (322) 322
adenocarcinoma (311) 311
stomach neoplasms - drug therapy (306) 306
randomized-trial (294) 294
cancer patients (293) 293
prospective studies (292) 292
colonic neoplasms - drug therapy (291) 291
deoxycytidine - adverse effects (291) 291
antibodies, monoclonal - administration & dosage (286) 286
adenocarcinoma - pathology (285) 285
pharmacology/toxicology (284) 284
colon cancer (280) 280
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4796) 4796
Japanese (34) 34
French (26) 26
German (18) 18
Chinese (8) 8
Spanish (8) 8
Korean (3) 3
Italian (2) 2
Polish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet, ISSN 0140-6736, 05/2019, Volume 393, Issue 10184, pp. 1948 - 1957
Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy... 
SURGERY | REGRESSION | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESECTION | CHEMORADIOTHERAPY | OPEN-LABEL | ESOPHAGEAL | CANCER | STOMACH | Capecitabine - administration & dosage | Leucovorin - administration & dosage | Adenocarcinoma - pathology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Oxaliplatin - therapeutic use | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Fluorouracil - therapeutic use | Docetaxel - administration & dosage | Fluorouracil - administration & dosage | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Oxaliplatin - administration & dosage | Administration, Oral | Esophagogastric Junction - pathology | Treatment Outcome | Capecitabine - therapeutic use | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Digestive System Surgical Procedures | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Docetaxel - therapeutic use | Aged | Neoplasm Staging | Adenocarcinoma | Anthracyclines | Chemotherapy | Leucovorin | Product development | Esophageal cancer | Cancer | Intravenous administration | Control methods | Toxicity | Clinical trials | Oncology | Metastasis | Cancer therapies | Stomach cancer | Metastases | Confidence intervals | Infusion | Oxaliplatin | Motivation | Surgery | Intravenous infusion | Epirubicin | Medical research | Survival | Patients | Cisplatin | Esophagus | Interactive systems | Medical prognosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 23, pp. 3786 - 3793
Purpose Data concerning the prevalence of and outcomes related to thromboembolic events (TEs) in patients with advanced gastroesophageal cancer who are... 
CISPLATIN-BASED CHEMOTHERAPY | PHASE-III TRIAL | BREAST-CANCER | FLUOROURACIL PLUS OXALIPLATIN | ONCOLOGY | ADVANCED ESOPHAGOGASTRIC CANCER | TESTICULAR CANCER | VASCULAR EVENTS | CENTRAL VENOUS CATHETERS | 1ST-LINE THERAPY | METASTATIC COLORECTAL-CANCER | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Anticoagulants - administration & dosage | Thromboembolism - chemically induced | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - pathology | Epirubicin - administration & dosage | Thromboembolism - epidemiology | Warfarin - administration & dosage | Antimetabolites, Antineoplastic - administration & dosage | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Incidence | Esophageal Neoplasms - complications | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Odds Ratio | Catheterization, Central Venous - adverse effects | Stomach Neoplasms - complications | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Esophagogastric Junction - pathology | Thromboembolism - etiology | Stomach Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Cisplatin - adverse effects | Aged | Esophageal Neoplasms - drug therapy | United Kingdom - epidemiology | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2014, Volume 32, Issue 31, pp. 3520 - 3526
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 13, pp. 1442 - 1450
Summary Background Poor prognosis germ-cell tumours are only cured in about half of patients. We aimed to assess whether treatment intensification based on an... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | 1ST CYCLE | ETOPOSIDE | THERAPY | SOUTHWEST-ONCOLOGY-GROUP | CISPLATIN | ONCOLOGY | DENSE CHEMOTHERAPY | HIGH-DOSE CHEMOTHERAPY | COMPLETE-RESPONSE | CANCER | Testicular Neoplasms - mortality | Prognosis | Follow-Up Studies | Peritoneal Neoplasms - blood | Humans | Middle Aged | Male | Mediastinal Neoplasms - mortality | Neoplasms, Germ Cell and Embryonal - blood | Testicular Neoplasms - pathology | Cisplatin - administration & dosage | Young Adult | Mediastinal Neoplasms - drug therapy | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Peritoneal Neoplasms - drug therapy | Oxaliplatin | Chorionic Gonadotropin - blood | Adult | Female | Neoplasms, Germ Cell and Embryonal - drug therapy | Paclitaxel - administration & dosage | Precision Medicine | alpha-Fetoproteins - metabolism | Peritoneal Neoplasms - pathology | Lenograstim | Mediastinal Neoplasms - blood | Neoplasms, Germ Cell and Embryonal - mortality | Etoposide - administration & dosage | Survival Rate | Bleomycin - administration & dosage | Peritoneal Neoplasms - mortality | Recombinant Proteins - administration & dosage | Biomarkers, Tumor - blood | Ifosfamide - administration & dosage | International Agencies | Testicular Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mediastinal Neoplasms - pathology | Adolescent | Aged | Neoplasm Staging | Testicular Neoplasms - blood | Neoplasms, Germ Cell and Embryonal - pathology | Granulocyte Colony-Stimulating Factor - administration & dosage | Chemotherapy | Tumors | Cancer | Analysis
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2009, Volume 20, Issue 11, pp. 1842 - 1847
Background: Bevacizumab significantly improves survival when added to chemotherapy for metastatic colorectal cancer (mCRC). The Bevacizumab Expanded Access... 
Expanded access study | Chemotherapy | First line | mCRC | Metastatic colorectal cancer | Bevacizumab | expanded access study | LEUCOVORIN | PHASE-II | first line | OXALIPLATIN | FLUOROURACIL | COMBINATION | chemotherapy | TRIAL | THERAPY | ONCOLOGY | bevacizumab | metastatic colorectal cancer | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Young Adult | Antibodies, Monoclonal, Humanized | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Deoxycytidine - adverse effects | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 853 - 860
Summary Background Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line... 
Hematology, Oncology and Palliative Medicine | TRIAL | CAPECITABINE | 1ST-LINE TREATMENT | INFUSIONAL FLUOROURACIL/LEUCOVORIN | THERAPY | ONCOLOGY | 5-FLUOROURACIL/FOLINIC ACID | FLUOROPYRIMIDINES | OXALIPLATIN | III NONINFERIORITY | FAILURE | Prodrugs - administration & dosage | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Fluorouracil - analogs & derivatives | Tegafur - adverse effects | Kaplan-Meier Estimate | Oxonic Acid - administration & dosage | Adenocarcinoma - drug therapy | Oxonic Acid - adverse effects | Disease-Free Survival | Prodrugs - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Drug Combinations | Adenocarcinoma - mortality | Medical colleges | Chemotherapy | Oncology, Experimental | Colorectal cancer | Leucovorin | Research | Metastasis | Cancer | Fluorouracil | Analysis
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2016, Volume 34, Issue 23, pp. 2736 - 2742
Purpose To determine the optimal chemotherapy backbone for testing in future US cooperative group studies for metastatic esophageal and gastroesophageal... 
GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | INFUSIONAL FLUOROURACIL | CISPLATIN | ONCOLOGY | COLORECTAL-CANCER | ADVANCED GASTRIC-CANCER | CLINICAL-TRIALS | ADVANCED ESOPHAGOGASTRIC CANCER | WEEKLY OXALIPLATIN | FOLINIC ACID | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Epirubicin - administration & dosage | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Treatment Failure | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Survival Rate | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease Progression | Disease-Free Survival | Esophagogastric Junction | Irinotecan | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Squamous Cell - secondary | Cetuximab - administration & dosage | Aged | Esophageal Neoplasms - drug therapy | Organoplatinum Compounds - adverse effects | Index Medicus | ORIGINAL REPORTS | Gic12
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2010, Volume 28, Issue 31, pp. 4706 - 4713
Panitumumab is a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS) in... 
SURVIVAL | 1ST-LINE TREATMENT | CONTROLLED-TRIAL | SUPPORTIVE CARE | ONCOLOGY | CETUXIMAB PLUS IRINOTECAN | KRAS | OXALIPLATIN | FAILURE | CHEMOTHERAPY | Leucovorin - administration & dosage | Predictive Value of Tests | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Chemotherapy, Adjuvant | Colorectal Neoplasms - metabolism | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Drug Administration Schedule | Kaplan-Meier Estimate | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Neoplasm Staging | Index Medicus
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 02/2014, Volume 106, Issue 2, pp. djt371 - djt371
Background Since the introduction of biologic therapies for the treatment of metastatic colorectal cancer (mCRC), few studies have examined patterns of care or... 
PANITUMUMAB | RANDOMIZED PHASE-3 TRIAL | 1ST-LINE TREATMENT | LEUCOVORIN | ONCOLOGY | BEVACIZUMAB | CETUXIMAB PLUS IRINOTECAN | OXALIPLATIN | FLUOROURACIL | III TRIAL | PROGRESSION | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | United States | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Practice Patterns, Physicians | Bevacizumab | Organoplatinum Compounds - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Retrospective Studies | Cetuximab | Molecular Targeted Therapy - methods | Recombinant Fusion Proteins - administration & dosage | Camptothecin - analogs & derivatives | Databases, Factual | Pyridines - administration & dosage | Proto-Oncogene Proteins - genetics | Cancer Care Facilities | Chemotherapy, Adjuvant - statistics & numerical data | Receptors, Vascular Endothelial Growth Factor - administration & dosage | Phenylurea Compounds - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Molecular Targeted Therapy - statistics & numerical data | Mutation | Colorectal Neoplasms - pathology | Cohort Studies | Care and treatment | Chemotherapy | Patient outcomes | Methods | Colorectal cancer | Cancer
Journal Article